Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 3;78(5):1175-1181.
doi: 10.1093/jac/dkad057.

Comparative effectiveness of β-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study

D T P Buis  1 , T W van der Vaart  2   3 , J M Prins  1 , J T M van der Meer  3 , M J M Bonten  2   4 , E Sieswerda  2   4 , C H van Werkhoven  2 , K C E Sigaloff  1 , B L Herpers  5 , R R Jansen  6 , W Rozemeijer  7 , R Soetekouw  8 , G van Twillert  9 , J Veenstra  10
Affiliations

Comparative effectiveness of β-lactams for empirical treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective cohort study

D T P Buis et al. J Antimicrob Chemother. .

Erratum in

Abstract

Objectives: Standard once-daily dosing of ceftriaxone may not lead to adequate antibiotic exposure in all cases of Staphylococcus aureus bacteraemia (SAB). Therefore, we compared clinical effectiveness of empirical antibiotic treatment with flucloxacillin, cefuroxime and ceftriaxone in adult patients with MSSA bacteraemia.

Methods: We analysed data from the Improved Diagnostic Strategies in Staphylococcus aureus bacteraemia (IDISA) study, a multicentre prospective cohort study of adult patients with MSSA bacteraemia. Duration of bacteraemia and 30 day SAB-related mortality were compared between the three groups using multivariable mixed-effects Cox regression analyses.

Results: In total, 268 patients with MSSA bacteraemia were included in the analyses. Median duration of empirical antibiotic therapy was 3 (IQR 2-3) days in the total study population. Median duration of bacteraemia was 1.0 (IQR 1.0-3.0) day in the flucloxacillin, cefuroxime and ceftriaxone groups. In multivariable analyses, neither ceftriaxone nor cefuroxime was associated with increased duration of bacteraemia compared with flucloxacillin (HR 1.08, 95% CI 0.73-1.60 and HR 1.22, 95% CI 0.88-1.71). In multivariable analysis, neither cefuroxime nor ceftriaxone was associated with higher 30 day SAB-related mortality compared with flucloxacillin [subdistribution HR (sHR) 1.37, 95% CI 0.42-4.52 and sHR 1.93, 95% CI 0.67-5.60].

Conclusions: In this study, we could not demonstrate a difference in duration of bacteraemia and 30 day SAB-related mortality between patients with SAB empirically treated with flucloxacillin, cefuroxime or ceftriaxone. Since sample size was limited, it is possible the study was underpowered to find a clinically relevant effect.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Examples of definition of bacteraemia duration. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.
Figure 2.
Figure 2.
Flow chart of the study.
See this image and copyright information in PMC

References

    1. van Hal SJ, Jensen SO, Vaska VL et al. Predictors of mortality in Staphylococcus aureus bacteremia. Clin Microbiol Rev 2012; 25: 362–86. 10.1128/CMR.05022-11 - DOI - PMC - PubMed
    1. Zelenitsky SA, Beahm NP, Iacovides H et al. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. J Antimicrob Chemother 2018; 73: 1888–94. 10.1093/jac/dky120 - DOI - PubMed
    1. Paul M, Zemer-Wassercug N, Talker O et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin Microbiol Infect 2011; 17: 1581–6. 10.1111/j.1469-0691.2010.03425.x - DOI - PubMed
    1. Bos JC, Prins JM, Mistício MC et al. Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone in adult severely ill sub-Saharan African patients: a population pharmacokinetic modelling study. J Antimicrob Chemother 2018; 73: 1620–9. 10.1093/jac/dky071 - DOI - PubMed
    1. van der Vaart TW, Prins JM, Soetekouw R et al. Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2022; 74: 1442–9. 10.1093/cid/ciab632 - DOI - PMC - PubMed